[1] SUI X J, LIU J J, YANG X F. Cerebrospinal fluid biomarkers of Alzheimer's disease[J]. Neurosci Bull,2014,30(2):233-242.
[2] BLENNOW K, ZETTERBERG H. Biomarkers for Alzheimer's disease: current status and prospects for the future[J]. J Intern Med,2018,284(6):643-663.
[3] MATTSSON N, ANDREASSON U, ZETTERBERG H,et al.Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol,2017,74(5):557-566.
[4] OLSSON B,LAUTNER R,ANDREASSON U,et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis[J]. Lancet Neurol,2016,15(7): 673-684.
[5] TZEN K Y, YANG S Y, CHEN T F, et al. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease[J]. ACS Chem Neurosci,2014, 5(9):830-836.
[6] KARRAN E, MERCKEN M, DE STROOPER B.The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics[J]. Nat Rev Drug Discov, 2011,10(5): 698-712.
[7] JOHN A, MCINTYR E, CURTIS J, et al. Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease[J]. Autoimmunity, 2015, 48(5):344-351.
[8] CHIU M J, YANG S Y, CHEN T F, et al. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease[J]. Curr Alzheimer Res,2012,9(10):1142-1148.
[9] TSAI C L, LIANG C S, LEE J T, et al. Associations between plasma biomarkers and cognition in patients with Alzheimer's disease and amnestic mild cognitive impairment: a cross-sectional and longitudinal study[J]. Nihon Rinsho,2019,8(11):1893-1907.
[10] AYTON S, DIOUF I, BUSH A I, et al. Alzheimer's disease neuroimaging initiative. Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study[J]. J Neurol Neurosurg Psychiatry,2018,89(5):456-460.
[11] YANG C C, CHIU M J, CHEN T F,et al. Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer's disease[J]. J Alzheimers Dis,2018,61(4):1323-1332. |
